SCHEMBL1266936

SCHEMBL1266936

COc1ccc(CNc2ccc(Cc3c[nH]c4ncccc34)cn2)cn1

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CSF1R P07333 4/20 0.67
KIT P10721 2/20 0.67
CYP2C19 P33261 6/20 0.58
CYP2C9 P11712 4/20 0.58
CYP3A4 P08684 9/20 0.57
FGFR1 P11362 1/20 0.53
FGFR4 P22455 1/20 0.53
CYP2D6 P10635 1/20 0.51
MET P08581 1/20 0.50
GPR84 Q9NQS5 1/20 0.49
FLT3 P36888 2/20 0.48
LCK P06239 1/20 0.48
PGR P06401 1/20 0.48
CHRM2 P08172 1/20 0.48
HTR1A P08908 1/20 0.48
ADRA2A P08913 1/20 0.48
PDGFRB P09619 1/20 0.48
ADORA3 P0DMS8 1/20 0.48
CHRM1 P11229 1/20 0.48
PDGFRA P16234 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30695630 0.89 CYP2C9 (0.72) CSF1RKITCYP2C19CYP2C9CYP3A4
SCHEMBL1884114 0.89 CYP2C9 (0.72) CSF1RKITCYP2C19CYP2C9CYP3A4
SCHEMBL19898655 0.89 CSF1R (0.74) CSF1RKITCYP2C19CYP2C9CYP3A4
SCHEMBL1268011 0.88 CSF1R (0.68) CSF1RKITCYP2C19CYP2C9CYP3A4
SCHEMBL858211 0.88 CSF1R (0.71) CSF1RKITCYP2C19CYP2C9CYP3A4
SCHEMBL1267534 0.87 CYP3A4 (0.61) CSF1RKITCYP2C19CYP2C9CYP3A4
SCHEMBL1267417 0.86 CYP3A4 (0.77) CSF1RKITCYP2C19CYP2C9CYP3A4
SCHEMBL1889536 0.86 CYP3A4 (0.61) CSF1RKITCYP2C19CYP2C9CYP3A4
SCHEMBL1267637 0.86 CSF1R (0.60) CSF1RKITCYP2C19CYP2C9CYP3A4
SCHEMBL1267815 0.86 CSF1R (0.73) CSF1RKITCYP2C19CYP2C9CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 66 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2709622-A2 KINASE MODULATION AND INDICATIONS THEREFOR PLEXXIKON INC. (US) 2014-03-26 EP claimed
US-20130274259-A1 KINASE MODULATION AND INDICATIONS THEREFOR DAIICHI SANKYO, INC. 2013-10-17 US claimed
US-8461169-B2 Compounds modulating c-fms and/or c-kit activity PLEXXIKON INC. (US) 2013-06-11 US claimed
US-8404700-B2 Compounds modulating c-fms and/or c-kit activity and uses therefor PLEXXIKON INC. (US) 2013-03-26 US claimed
US-20120309756-A1 COMPOUNDS MODULATING C-FMS AND/OR C-KIT ACTIVITY AND USES THEREFOR PLEXXIKON INC 2012-12-06 US claimed
WO-2012158957-A2 KINASE MODULATION AND INDICATIONS THEREFOR PLEXXIKON INC. (US) 2012-11-22 WO claimed
US-20110230482-A1 COMPOUNDS MODULATING C-FMS AND/OR C-KIT ACTIVITY PLEXXIKON INC. 2011-09-22 US claimed
US-7893075-B2 Compounds modulating c-fms and/or c-kit activity and uses therefor PLEXXIKON, INC. (US) 2011-02-22 US claimed
EP-2086972-A2 COMPOUNDS MODULATING C-FMS AND/OR C-KIT ACTIVITY AND USES THEREFOR PLEXXIKON, INC. (US) 2009-08-12 EP claimed
US-20090076046-A1 Compounds modulating c-fms and/or c-kit activity and uses therefor PLEXXIKON INC 2009-03-19 US claimed
WO-2008064255-A2 COMPOUNDS MODULATING C-FMS AND/OR C-KIT ACTIVITY AND USES THEREFOR PLEXXIKON, INC. (US) 2008-05-29 WO claimed
WO-2008064265-A2 COMPOUNDS MODULATING C-FMS AND/OR C-KIT ACTIVITY AND USES THEREFOR PLEXXIKON, INC. (US) 2008-05-29 WO claimed
WO-2008063888-A2 COMPOUNDS MODULATING C-FMS AND/OR C-KIT ACTIVITY AND USES THEREFOR PLEXXIKON, INC. (US) 2008-05-29 WO claimed
EP-4295912-A2 COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR Daiichi Sankyo, Inc. (US) 2023-12-27 EP disclosed
US-20190263800-A1 COMPOUNDS MODULATING C-FMS AND/OR C-KIT ACTIVITY AND USES THEREFOR PLEXXIKON INC. 2019-08-29 US disclosed
US-20190263800-A1 COMPOUNDS MODULATING C-FMS AND/OR C-KIT ACTIVITY AND USES THEREFOR PLEXXIKON INC. 2019-08-29 US disclosed
US-20090076046-A1 Compounds modulating c-fms and/or c-kit activity and uses therefor PLEXXIKON INC 2009-03-19 US disclosed
US-20090076046-A1 Compounds modulating c-fms and/or c-kit activity and uses therefor PLEXXIKON INC 2009-03-19 US disclosed
US-20090076046-A1 Compounds modulating c-fms and/or c-kit activity and uses therefor PLEXXIKON INC 2009-03-19 US disclosed
WO-2008064255-A2 COMPOUNDS MODULATING C-FMS AND/OR C-KIT ACTIVITY AND USES THEREFOR PLEXXIKON, INC. (US) 2008-05-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130274259-A1 KINASE MODULATION AND INDICATIONS THEREFOR FLT3, MET, BTK CSF1R 33/4885KIT 138/4885CYP2C19 4477/4885
US-20090076046-A1 Compounds modulating c-fms and/or c-kit activity and uses therefor KIT, FLT3, FLT1 CSF1R 4/4885KIT 1/4885CYP2C19 3327/4885
US-20120309756-A1 COMPOUNDS MODULATING C-FMS AND/OR C-KIT ACTIVITY AND USES THEREFOR KIT, FLT3, FLT1 CSF1R 4/4885KIT 1/4885CYP2C19 3327/4885
US-20110230482-A1 COMPOUNDS MODULATING C-FMS AND/OR C-KIT ACTIVITY KIT, FLT3, FER CSF1R 10/4885KIT 1/4885CYP2C19 3400/4885
US-20190263800-A1 COMPOUNDS MODULATING C-FMS AND/OR C-KIT ACTIVITY AND USES THEREFOR KIT, FLT3, FLT1 CSF1R 4/4885KIT 1/4885CYP2C19 3359/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.